Evaluation of chronic lymphocytic leukemia by oligonucleotide-based microarray analysis uncovers novel aberrations not detected by FISH or cytogenetic analysis

[1]  S. Gunn,et al.  Clinical Application of Array-Based Comparative Genomic Hybridization for the Identification of Prognostically Important Genetic Alterations in Chronic Lymphocytic Leukemia , 2012, Molecular Diagnosis & Therapy.

[2]  F. Bertoni,et al.  B‐Cell Chronic Lymphocytic Leukaemia , 2011 .

[3]  A Collins,et al.  13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia , 2011, Leukemia.

[4]  R. Rosenquist,et al.  The novel NF-κB inhibitor IMD-0354 induces apoptosis in chronic lymphocytic leukemia , 2011, Blood cancer journal.

[5]  D. V. Dyke.  18 or trisomy 18 in lymphoproliferative disorders , 2011 .

[6]  S. Giannouli,et al.  GSTT1 and GSTM1 polymorphisms and myelodysplastic syndrome risk: a systematic review and meta‐analysis , 2010, International journal of cancer.

[7]  S. Kash,et al.  Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays. , 2010, The Journal of molecular diagnostics : JMD.

[8]  T. Shanafelt,et al.  A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B‐chronic lymphocytic leukaemia , 2010, British journal of haematology.

[9]  Andrea Califano,et al.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. , 2010, Cancer cell.

[10]  P. Lichter.  All you need is a Mir-acle: the role of nontranslated RNAs in the suppression of B cell chronic lymphocytic leukemia. , 2010, Cancer cell.

[11]  K. Coombes,et al.  Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. , 2009, Leukemia research.

[12]  B. Lakshmi,et al.  Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). , 2009, Blood.

[13]  T. Shanafelt.  Predicting clinical outcome in CLL: how and why. , 2009, Hematology. American Society of Hematology. Education Program.

[14]  L. Abruzzo,et al.  Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. , 2009, The Journal of molecular diagnostics : JMD.

[15]  M. Lowery-Nordberg,et al.  Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia , 2009, Leukemia.

[16]  Francesco Bertoni,et al.  Genome‐wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion , 2008, British journal of haematology.

[17]  G. Mufti,et al.  Whole genome scanning as a cytogenetic tool in hematologic malignancies. , 2008, Blood.

[18]  A. C. Chinault,et al.  Validation of a targeted DNA microarray for the clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia , 2008, American journal of hematology.

[19]  K. Do,et al.  Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Siebert,et al.  Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B‐chronic lymphocytic leukaemia , 2007, British journal of haematology.

[21]  C. Croce,et al.  CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control , 2006, Proceedings of the National Academy of Sciences.

[22]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[23]  F. Rieux-Laucat,et al.  Autoimmune lymphoproliferative syndrome with somatic Fas mutations. , 2004, The New England journal of medicine.

[24]  A. Veronese,et al.  Chronic lymphocytic leukemia with 6q− shows distinct hematological features and intermediate prognosis , 2004, Leukemia.

[25]  J. Byrd,et al.  Chronic lymphocytic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.

[26]  N. Takahashi,et al.  Protocadherin LKC, a new candidate for a tumor suppressor of colon and liver cancers, its association with contact inhibition of cell proliferation. , 2002, Carcinogenesis.

[27]  R. Eeles,et al.  Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. , 2002, Blood.

[28]  N. Carpenter,et al.  Molecular cytogenetics , 2001, Seminars in pediatric neurology.

[29]  M. Seto,et al.  A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue , 1999, Oncogene.

[30]  J C Reed,et al.  Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases , 1999, The EMBO journal.

[31]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[32]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[33]  R. Foà,et al.  Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. , 1999, Blood.

[34]  A. Kumagai,et al.  The cdc25 protein contains an intrinsic phosphatase activity , 1991, Cell.

[35]  Mark J. Thomas,et al.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.

[36]  D C Case,et al.  Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.